A Phase 1/2 interventional study of Mosunetuzumab and Polatuzumab Vedotin in B-cell Non-Hodgkin Lymphoma, sponsored by Hoffmann-La Roche. Completed at 41 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-18.
Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing polatuzumab vedotin in Lymphoma, B-Cell — 5 open to participants now, 8 under way, none of them phase 3. polatuzumab vedotin · Lymphoma, B-Cell.
Among the 11 studies testing polatuzumab vedotin in Lymphoma, B-Cell, this one is the 2nd largest by enrollment, is the only one that started in 2019, is one of 2 in phase 1/2, and was the 2nd registered.
885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.
Browse Lymphoma, B-Cell studies →5 of the 11 studies testing polatuzumab vedotin in Lymphoma, B-Cell are open now, in 4 countries. Recruiting first, the newest first:
National Research Center for Hematology, Russia · Sites in Russia
Ages 18+
University College, London · Sites in United Kingdom
Ages 18+
New York Medical College · Sites in United States
Ages 12–70
Brown University · Sites in United States
Ages 18+
Ruijin Hospital · Sites in China
Ages 70+
By country, each count listing its studies:
polatuzumab vedotin: first FDA approval 2019 (POLIVY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 9
First in 2018; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 117 is above the median of 34 across 773 interventional studies indexed under Lymphoma, B-Cell.
Median enrollment 40 across the 11 interventional studies. Of the 3 that completed or were terminated, 2 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 11 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 9 studies filed under Lymphoma, B-Cell — fewer than ten, so there is no comparison to draw.
2 of the studies testing polatuzumab vedotin in Lymphoma, B-Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06071871University College, LondonA Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma | 2027-07-30 |
| NCT04594798University of RochesterA Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL | 2027-07-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies testing polatuzumab vedotin in Lymphoma, B-Cell, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (M-CHOP) and, subsequently, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) plus polatuzumab vedotin (CHP-pola) in participants with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL), and in previously untreated participants with diffuse large B-cell lymphoma (DLBCL).
Inclusion Criteria for Phase Ib and Phase II Portions
Inclusion Criteria for Phase Ib Portion
Participants must also meet the following criteria for study entry into the Phase Ib portion:
Inclusion Criteria for Phase II Portion
Participants must also meet the following criteria for study entry in the Phase II portion:
Exclusion Criteria
Exclusion Criteria for Phase Ib Portion
Participants who also meet any of the following criteria will be excluded from study entry in the Phase Ib portion:
Exclusion Criteria for Phase II Portion
Participants who also meet any of the following criteria will be excluded from study entry in the Phase II portion:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive M-CHOP up to the phase II recommended dose (RP2D).
Drug: Mosunetuzumab · Drug: Polatuzumab Vedotin · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone · Drug: Tocilizumab
Participants will receive M-CHP-Pola up to the RP2D.
Drug: Mosunetuzumab · Drug: Polatuzumab Vedotin · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Prednisone · Drug: Tocilizumab
Participants with 1L DLBCL will receive mosunetuzumab at the RP2D in combination with CHOP.
Drug: Mosunetuzumab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone · Drug: Tocilizumab
Participants with 1L DLBCL will receive M-CHP-Pola at a dose determined in the dose finding stage.
Drug: Mosunetuzumab · Drug: Polatuzumab Vedotin · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Prednisone · Drug: Tocilizumab
Participants with 1L DLBCL will receive R-CHP-Pola at a dose determined in the dose finding stage.
Drug: Polatuzumab Vedotin · Drug: Rituxumab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Prednisone
Participants with 1L DLBCL will receive M-CHOP at a dose determined in the dose finding stage. NOTE: No participants were enrolled to this arm.
Drug: Mosunetuzumab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone · Drug: Tocilizumab
Participants will receive intravenous (IV) mosunetuzumab.
Participants will receive polatuzumab vedotin via IV.
Participants will receive rituxumab via IV.
Participants will receive cyclophosphamide via IV.
Participants will receive doxorubicin via IV.
Participants will receive vincristine via IV.
Participants will receive oral prednisone.
Participants will receive tocilizumab via IV.
Complete Response (CR) Rate at the Time of Primary Response Assessment (PRA) Based on Positron Emission Tomography - Computed Tomography (PET-CT) as Determined by Independent Review Committee (IRC)
The CR rate was defined as the percentage of participants with CR. Assessments were made according to the Lugano 2014 Response Criteria.
Time frame: 6-8 weeks after either C6D1 or last dose of study treatment
CR Rate at PRA Based on CT Only as Determined by the Investigator (Phase II)
Time frame: 6-8 weeks after C6D1 or last dose of study treatment
Overall Response Rate (ORR) at PRA Based on PET-CT as Determined by the Investigator (Phase II)
ORR is defined as a CR or PR at the time of primary assessment based on PET-CT, as determined by the investigator.
Time frame: 6-8 weeks after C6D1 or last dose of study treatment
ORR at PRA Based on CT Only as Determined by the Investigator (Phase II)
ORR is defined as a CR or PR at the time of primary assessment based on CT only, as determined by the investigator.
Time frame: 6-8 weeks after C6D1 or last dose of study treatment
Best ORR Based on PET-CT and/or CT Scan as Determined by the Investigator (Phase II)
Best ORR was defined as CR or PR at any time on study and based on PET-CT or CT only as determined by the investigator.
Time frame: Up to approximately 50 months
Duration of Response (DOR) as Determined by the Investigator (Phase II)
DOR is defined as the time from the first occurrence of a documented objective response to disease progression or relapse as determined by the investigator, or death from any cause, whichever occurs first. The range values (min-max) are based on censored observations (if a participant did not experience disease progression or death prior to the end of the trial DOR was censored on the date of the last tumor assessment).
Time frame: Up to approximately 50 months
Progression-free Survival (PFS) as Determined by the Investigator (Phase II)
PFS is defined as the time from randomization to the first occurrence of disease progression or relapse as determined by the investigator, or death from any cause, whichever occurs first. The earliest contributing event to PFS is reported. The range (min-max) values are based on censored observations (participants without a baseline-evaluable tumor assessment were censored at the date of randomization or first study treatment, plus 1 day).
Time frame: Up to approximately 50 months
PFS at 1 Year as Determined by the Investigator (Phase II)
PFS at 1 year is defined as the proportion of participants with disease progression or relapse as determined by the investigator, or death from any cause within 1 year of randomization.
Time frame: 1 year
Event-free Survival (EFS) as Determined by the Investigator (Phase II)
EFS is defined as the time from randomization to the first occurrence of disease progression or relapse, as determined by the investigator, initiation of new anti-lymphoma therapy (NALT), or death from any cause, whichever occurs first. The range values (min-max) are based on censored observations (if a participant did not experience disease progression or death prior to the end of the trial DOR was censored on the date of the last tumor assessment).
Time frame: Up to 50 months
Time to Deterioration in Lymphoma Symptoms as Measured by the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Subscale
Time frame: C1D1 through follow-up period (to begin 2 years after PRA or at the time of study drug discontinuation)
Time to Deterioration in Physical Functioning and Fatigue as Measured by the European Organization for Research and Treatment of Cancer Quality of Life - Core 30 Questionnaire (EORTC QLQ-C30)
Time frame: C1D1 through follow-up period (to begin 2 years after PRA or at the time of study drug discontinuation)
Polatuzumab Vedotin Serum Concentrations
Time frame: C2D1, C6D1
Polatuzumab Vedotin Antibody-conjugated Monomethyl Auristatin E (acMMAE) Serum Concentrations
Time frame: C1D1-C6D1
Polatuzumab Vedotin Unconjugated Mono-methyl Auristatin E (MMAE) Serum Concentrations
Time frame: C1D1-C6D1
Mosunetuzumab Serum Concentrations
Time frame: C1D1-C5D1
Baseline Prevalence and Incidence of Treatment Emergent Anti-drug Antibodies (ADA) to Mosunetuzumab
Participants are considered to have treatment-induced ADA responses if they are ADA negative or missing data at baseline and then develop an ADA response following study drug administration. Participants are considered to have treatment-enhanced ADA responses if they are ADA positive at baseline and the titer of one or more post baseline samples is at least 4-fold greater than the titer of the baseline sample. Patients are considered to be negative for ADAs if they are ADA negative at all timepoints or if they are ADA positive at baseline but do not have any post-baseline samples with a titer that is at least 4-fold greater than the titer of the baseline sample (treatment unaffected).
Time frame: Cycles 1, 2, 6, 16, and at early discontinuation visit or at PRA (6-8 weeks after either C6D1 or last dose of study treatment)
Baseline Prevalence and Incidence of Treatment Emergent ADA to Polatuzumab Vedotin
Participants are considered to have treatment-induced ADA responses if they are ADA negative or missing data at baseline and then develop an ADA response following study drug administration. Participants are considered to have treatment-enhanced ADA responses if they are ADA positive at baseline and the titer of one or more post baseline samples is at least 4-fold greater than the titer of the baseline sample. Patients are considered to be negative for ADAs if they are ADA negative at all timepoints or if they are ADA positive at baseline but do not have any post-baseline samples with a titer that is at least 4-fold greater than the titer of the baseline sample (treatment unaffected).
Time frame: Cycles 1, 2, 6, and at early discontinuation visit or at PRA (6-8 weeks after either C6D1 or last dose of study treatment)
| Milestone | Group A1: Phase Ib Mosunetuzumab + CHOP | Group A2: Phase Ib Mosunetuzumab + CHOP | Group B: Phase Ib Mosunetuzumab + CHP-Pola | Group C: Phase II Mosunetuzumab + CHOP | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) |
|---|---|---|---|---|---|---|
| Started | 3 | 4 | 8 | 40 | 40 | 22 |
| Completed | 1 | 3 | 1 | 28 | 31 | 19 |
| Not completed | 2 | 1 | 7 | 12 | 9 | 3 |
| Withdrew: Death | 2 | 1 | 6 | 9 | 5 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Screen failure or enrolled in error | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 1 | 1 | 0 |
The CR rate was defined as the percentage of participants with CR. Assessments were made according to the Lugano 2014 Response Criteria.
| Percentage of participants | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) |
|---|---|---|
| Complete Response (CR) Rate at the Time of Primary Response Assessment (PRA) Based on Positron Emission Tomography - Computed Tomography (PET-CT) as Determined by Independent Review Committee (IRC) | 72.5 (56.11 to 85.40) | 77.3 (54.63 to 92.18) |
| Percentage of participants | Group C: Phase II Mosunetuzumab + CHOP | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) |
|---|---|---|---|
| CR Rate at PRA Based on CT Only as Determined by the Investigator (Phase II) | 50.0 (33.80 to 66.20) | 47.5 (31.51 to 63.87) | 31.8 (13.86 to 54.87) |
ORR is defined as a CR or PR at the time of primary assessment based on PET-CT, as determined by the investigator.
| Percentage of participants | Group C: Phase II Mosunetuzumab + CHOP | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) |
|---|---|---|---|
| Overall Response Rate (ORR) at PRA Based on PET-CT as Determined by the Investigator (Phase II) | 87.5 (73.20 to 95.81) | 80.0 (64.35 to 90.95) | 77.3 (54.63 to 92.18) |
ORR is defined as a CR or PR at the time of primary assessment based on CT only, as determined by the investigator.
| Percentage of participants | Group C: Phase II Mosunetuzumab + CHOP | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) |
|---|---|---|---|
| ORR at PRA Based on CT Only as Determined by the Investigator (Phase II) | 85.0 (70.16 to 94.29) | 72.5 (56.11 to 85.40) | 81.8 (59.72 to 94.81) |
Best ORR was defined as CR or PR at any time on study and based on PET-CT or CT only as determined by the investigator.
| Percentage of responders | Group C: Phase II Mosunetuzumab + CHOP | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) |
|---|---|---|---|
| Best ORR Based on PET-CT and/or CT Scan as Determined by the Investigator (Phase II) | 95.0 (83.08 to 99.39) | 85.0 (70.16 to 94.29) | 95.5 (77.16 to 99.88) |
DOR is defined as the time from the first occurrence of a documented objective response to disease progression or relapse as determined by the investigator, or death from any cause, whichever occurs first. The range values (min-max) are based on censored observations (if a participant did not experience disease progression or death prior to the end of the trial DOR was censored on the date of the last tumor assessment).
| Months | Group C: Phase II Mosunetuzumab + CHOP | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) |
|---|---|---|---|
| Duration of Response (DOR) as Determined by the Investigator (Phase II) | NA (0 to 28) | NA (0 to 28) | NA (1 to 27) |
PFS is defined as the time from randomization to the first occurrence of disease progression or relapse as determined by the investigator, or death from any cause, whichever occurs first. The earliest contributing event to PFS is reported. The range (min-max) values are based on censored observations (participants without a baseline-evaluable tumor assessment were censored at the date of randomization or first study treatment, plus 1 day).
| Months | Group C: Phase II Mosunetuzumab + CHOP | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) |
|---|---|---|---|
| Progression-free Survival (PFS) as Determined by the Investigator (Phase II) | NA (0 to 31) | NA (0 to 30) | NA (3 to 30) |
PFS at 1 year is defined as the proportion of participants with disease progression or relapse as determined by the investigator, or death from any cause within 1 year of randomization.
| Percentage of participants | Group C: Phase II Mosunetuzumab + CHOP | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) |
|---|---|---|---|
| PFS at 1 Year as Determined by the Investigator (Phase II) | 77.47 (63.65 to 91.29) | 70.83 (55.59 to 86.07) | 81.82 (65.70 to 97.94) |
EFS is defined as the time from randomization to the first occurrence of disease progression or relapse, as determined by the investigator, initiation of new anti-lymphoma therapy (NALT), or death from any cause, whichever occurs first. The range values (min-max) are based on censored observations (if a participant did not experience disease progression or death prior to the end of the trial DOR was censored on the date of the last tumor assessment).
| Months | Group C: Phase II Mosunetuzumab + CHOP | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) |
|---|---|---|---|
| Event-free Survival (EFS) as Determined by the Investigator (Phase II) | NA (2 to 31) | NA (0 to 30) | NA (3 to 30) |
| Months | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) |
|---|---|---|
| Time to Deterioration in Lymphoma Symptoms as Measured by the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Subscale | NA (2.3 to NA) | 6.5 (2.1 to NA) |
| Months | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) |
|---|---|---|
| Time to Deterioration in Physical Functioning and Fatigue as Measured by the European Organization for Research and Treatment of Cancer Quality of Life - Core 30 Questionnaire (EORTC QLQ-C30) | 2.3 (1.2 to 5.4) | 2.3 (0.8 to NA) |
| ug/mL | Group B: Phase Ib Mosunetuzumab + CHP-Pola | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) |
|---|---|---|---|
| C2D1 pre-dose | 0.993 ± 779.4 | 1.99 ± 80.7 | 1.73 ± 107.9 |
| C6D1 pre-dose | 2.76 ± 820.1 | 8.13 ± 34.5 | 5.8 ± 42 |
| ng/mL | Group B: Phase Ib Mosunetuzumab + CHP-Pola | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) |
|---|---|---|---|
| C1D1 post-dose | 620 ± 54.5 | 668 ± 21.2 | 584 ± 23.1 |
| C1D2 pre-dose | 219 ± 412.2 | — | — |
| C1D2 24hrs post-dose | 115 ± 658.3 | 275 ± 28.2 | — |
| C1D8 pre-dose | 23 ± 1040.4 | 42 ± 82 | — |
| C1D15 pre-dose | 8.22 ± 550.4 | 13.2 ± 87.4 | — |
| C2D1 pre-dose | 4.87 ± 626 | 6.81 ± 80.1 | 7.09 ± 95.5 |
| C2D1 post-dose | 656 ± 21.1 | 653 ± 18 | 654 ± 21 |
| C3D1 pre-dose | 19.2 ± 58.7 | 15.8 ± 39.5 | — |
| C3D1 post-dose | 144 ± 112947.3 | 544 ± 90.7 | — |
| C4D1 pre-dose | 16.8 ± 79.6 | 16.8 ± 50.3 | 15.6 ± 41.4 |
| C4D1 post-dose | 783 ± 26.5 | 614 ± 15.4 | 696 ± 24.1 |
| C5D1 pre-dose | 7.14 ± 343.5 | 19 ± 39.7 | — |
| C5D1 post-dose | 544 ± 37.6 | 605 ± 21.6 | — |
| C6D1 pre-dose | 11.8 ± 476.6 | 21.2 ± 34.7 | 17.3 ± 40.8 |
| ng/mL | Group B: Phase Ib Mosunetuzumab + CHP-Pola | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) |
|---|---|---|---|
| C1D1 post-dose | 0.535 ± 464.6 | 0.55 ± 71.1 | 0.432 ± 78.8 |
| C1D2 pre-dose | 1.94 ± 114.2 | — | — |
| C1D2 24hrs post-dose | 3.3 ± 97.8 | 2.82 ± 51.9 | — |
| C1D8 pre-dose | 2.95 ± 80.9 | 1.27 ± 93.6 | — |
| C1D15 pre-dose | 0.604 ± 113.3 | 0.301 ± 104.1 | — |
| C2D1 pre-dose | 0.187 ± 47.3 | 0.0773 ± 110.2 | 0.0697 ± 87 |
| C2D1 post-dose | 0.238 ± 64 | 0.137 ± 84 | 0.116 ± 56.3 |
| C3D1 pre-dose | 0.168 ± 92 | 0.146 ± 96.9 | — |
| C3D1 post-dose | 0.111 ± 173.9 | 0.203 ± 92.7 | — |
| C4D1 pre-dose | 0.0491 ± NA | 0.14 ± 93.8 | 0.106 ± 88.9 |
| C4D1 post-dose | 0.0825 ± 188.3 | 0.186 ± 66.1 | 0.164 ± 43.6 |
| C5D1 pre-dose | 0.0741 ± 247 | 0.137 ± 74.4 | — |
| C5D1 post-dose | 0.212 ± 54.2 | 0.17 ± 38.1 | — |
| C6D1 pre-dose | 0.0967 ± 194.2 | 0.142 ± 63.8 | 0.0974 ± 82.4 |
| ug/mL | Group A1: Phase Ib Mosunetuzumab + CHOP | Group A2: Phase Ib Mosunetuzumab + CHOP | Group B: Phase Ib Mosunetuzumab + CHP-Pola | Group C: Phase II Mosunetuzumab + CHOP | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) |
|---|---|---|---|---|---|
| C1D1 post-dose | 0.157 ± 22.1 | 0.181 ± 26.7 | — | 0.155 ± 34.1 | 0.132 ± 73.2 |
| C1D1 2 hrs post-dose | 0.152 ± 27.8 | 0.163 ± 25.8 | — | 0.151 ± 28.1 | — |
| C1D2 2 hrs post-dose | — | — | 0.145 ± 80 | — | — |
| C1D2 24 hrs post-dose | 0.103 ± 23.3 | 0.112 ± 8.1 | 0.0947 ± 60.2 | 0.096 ± 35.7 | 0.0825 ± 46.1 |
| C1D8 pre-dose | 0.0331 ± 49 | 0.0218 ± 153.2 | 0.0334 ± 113.6 | 0.0253 ± 62.2 | 0.0263 ± 77 |
| C1D8 post-dose | 0.342 ± 18.8 | 0.427 ± 36.2 | 0.354 ± 36.9 | 0.426 ± 30.3 | 0.376 ± 38.8 |
| C1D8 2hrs post-dose | 0.32 ± 28.5 | 0.409 ± 50.1 | 0.349 ± 43.1 | 0.388 ± 27.6 | — |
| C1D15 pre-dose | 0.0866 ± 47.9 | 0.0884 ± 52.8 | 0.0911 ± 57.7 | 0.0953 ± 41.8 | 0.102 ± 47.7 |
| C1D15 post-dose | 2.83 ± 22.6 | 5.71 ± 38.6 | 5.72 ± 44 | 7.13 ± 27.7 | 6.31 ± 34.8 |
| C1D15 2 hrs post-dose | 2.28 ± 7.5 | 5.66 ± 38.7 | 5.92 ± 18.5 | 6.56 ± 28.4 | — |
| C2D1 pre-dose | 0.549 ± 24.3 | 1.52 ± 49.4 | — | 1.67 ± 32.1 | 1.46 ± 62.8 |
| C2D1 post-dose | 2.86 ± 7.2 | 6.75 ± 42.2 | — | 8.31 ± 27.4 | 7.69 ± 38.3 |
| C2D1 2 hrs post-dose | 2.38 ± 1.2 | 7.33 ± 44.7 | 7.65 ± 35.1 | 8.28 ± 26.7 | — |
| C2D2 pre-dose | — | — | 1.37 ± 38.6 | — | — |
| C2D2 post-dose | — | — | 8.9 ± 34.1 | — | — |
| C3D1 pre-dose | 0.458 ± 36.3 | 1.08 ± 53.3 | 1.21 ± 45.1 | 1.11 ± 30.2 | 0.885 ± 43 |
| C3D1 post-dose | 3.37 ± 23.4 | 7.19 ± 30.8 | 6.66 ± 41.3 | 7.3 ± 39.2 | 6.76 ± 28.9 |
| C4D1 pre-dose | 0.502 ± 36.9 | 1.09 ± 44.4 | 0.782 ± 90 | 1.03 ± 33.9 | 0.932 ± 52 |
| C4D1 post-dose | 3.24 ± 31.3 | 7.38 ± 26.3 | 4.09 ± 83 | 7.41 ± 44 | 5.55 ± 80.3 |
| C5D1 pre-dose | 0.426 ± 51.7 | 1.02 ± 62 | 0.33 ± 176.6 | 1.12 ± 31.6 | 0.935 ± 106.1 |
Participants are considered to have treatment-induced ADA responses if they are ADA negative or missing data at baseline and then develop an ADA response following study drug administration. Participants are considered to have treatment-enhanced ADA responses if they are ADA positive at baseline and the titer of one or more post baseline samples is at least 4-fold greater than the titer of the baseline sample. Patients are considered to be negative for ADAs if they are ADA negative at all timepoints or if they are ADA positive at baseline but do not have any post-baseline samples with a titer that is at least 4-fold greater than the titer of the baseline sample (treatment unaffected).
| Number of participants | Group A1: Phase Ib Mosunetuzumab + CHOP | Group A2: Phase Ib Mosunetuzumab + CHOP | Group B: Phase Ib Mosunetuzumab + CHP-Pola | Group C: Phase II Mosunetuzumab + CHOP | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) |
|---|---|---|---|---|---|
| Positive sample at baseline | 0 | 0 | 0 | 0 | 0 |
| Not positive at baseline | 3 | 4 | 8 | 38 | 33 |
| Positive for treatment-emergent ADA | 0 | 0 | 0 | 0 | 0 |
| Positive for treatment-induced ADA | 0 | 0 | 0 | 0 | 0 |
| Positive for treatment-enhanced ADA | 0 | 0 | 0 | 0 | 0 |
| Negative for treatment-emergent ADA | 3 | 4 | 6 | 39 | 37 |
Participants are considered to have treatment-induced ADA responses if they are ADA negative or missing data at baseline and then develop an ADA response following study drug administration. Participants are considered to have treatment-enhanced ADA responses if they are ADA positive at baseline and the titer of one or more post baseline samples is at least 4-fold greater than the titer of the baseline sample. Patients are considered to be negative for ADAs if they are ADA negative at all timepoints or if they are ADA positive at baseline but do not have any post-baseline samples with a titer that is at least 4-fold greater than the titer of the baseline sample (treatment unaffected).
| Number of participants | Group B: Phase Ib Mosunetuzumab + CHP-Pola | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) |
|---|---|---|---|
| Positive sample at baseline | 0 | 1 | 2 |
| Not positive at baseline | 8 | 32 | 19 |
| Positive for treatment-emergent ADA | 0 | 0 | 1 |
| Positive for treatment-induced ADA | 0 | 0 | 1 |
| Positive for treatment-enhanced ADA | 0 | 0 | 0 |
| Negative for treatment-emergent ADA | 6 | 37 | 20 |
Collected over Up to approximately 30 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A1: Phase Ib Mosunetuzumab + CHOP | 2/3 (66.7%) | 3/3 (100%) | 3/3 (100%) |
| Group A2: Phase Ib Mosunetuzumab + CHOP | 1/4 (25%) | 4/4 (100%) | 4/4 (100%) |
| Group B: Phase Ib Mosunetuzumab + CHP-Pola | 6/8 (75%) | 6/8 (75%) | 8/8 (100%) |
| Group C: Phase II Mosunetuzumab + CHOP | 9/40 (22.5%) | 20/40 (50%) | 40/40 (100%) |
| Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | 5/40 (12.5%) | 24/38 (63.2%) | 38/38 (100%) |
| Arm 2: Phase II Rituximab + CHP-Pola (Randomized) | 3/22 (13.6%) | 3/22 (13.6%) | 22/22 (100%) |
| Event | Group A1: Phase Ib Mosunetuzumab + CHOP | Group A2: Phase Ib Mosunetuzumab + CHOP | Group B: Phase Ib Mosunetuzumab + CHP-Pola | Group C: Phase II Mosunetuzumab + CHOP | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) |
|---|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 0/3 | 2/4 | 0/8 | 6/40 | 5/38 | 1/22 |
| Supraventricular tachycardiaCardiac disorders | 1/3 | 0/4 | 0/8 | 0/40 | 0/38 | 0/22 |
| Pneumocystis jirovecii pneumoniaInfections and infestations | 1/3 | 0/4 | 0/8 | 0/40 | 0/38 | 0/22 |
| SepsisInfections and infestations | 1/3 | 1/4 | 0/8 | 0/40 | 0/38 | 0/22 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/3 | 0/4 | 0/8 | 1/40 | 0/38 | 0/22 |
| HypotensionVascular disorders | 1/3 | 0/4 | 0/8 | 0/40 | 0/38 | 0/22 |
| AnaemiaBlood and lymphatic system disorders | 0/3 | 0/4 | 2/8 | 1/40 | 2/38 | 0/22 |
| Cytokine release syndromeImmune system disorders | 0/3 | 1/4 | 0/8 | 0/40 | 5/38 | 0/22 |
| COVID-19Infections and infestations | 0/3 | 0/4 | 2/8 | 0/40 | 1/38 | 0/22 |
| PneumoniaInfections and infestations | 0/3 | 1/4 | 0/8 | 3/40 | 0/38 | 0/22 |
| Event | Group A1: Phase Ib Mosunetuzumab + CHOP | Group A2: Phase Ib Mosunetuzumab + CHOP | Group B: Phase Ib Mosunetuzumab + CHP-Pola | Group C: Phase II Mosunetuzumab + CHOP | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/3 | 1/4 | 6/8 | 22/40 | 17/38 | 9/22 |
| AnaemiaBlood and lymphatic system disorders | 2/3 | 2/4 | 2/8 | 17/40 | 9/38 | 5/22 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/3 | 1/4 | 3/8 | 5/40 | 6/38 | 1/22 |
| DiarrhoeaGastrointestinal disorders | 2/3 | 1/4 | 2/8 | 12/40 | 12/38 | 4/22 |
| Oedema peripheralGeneral disorders | 2/3 | 2/4 | 2/8 | 8/40 | 5/38 | 0/22 |
| FallInjury, poisoning and procedural complications | 2/3 | 0/4 | 2/8 | 0/40 | 0/38 | 0/22 |
| Platelet count decreasedInvestigations | 2/3 | 1/4 | 1/8 | 5/40 | 4/38 | 3/22 |
| Decreased appetiteMetabolism and nutrition disorders | 2/3 | 2/4 | 4/8 | 15/40 | 11/38 | 1/22 |
| HypomagnesaemiaMetabolism and nutrition disorders | 2/3 | 1/4 | 5/8 | 6/40 | 4/38 | 0/22 |
| Neuropathy peripheralNervous system disorders | 2/3 | 0/4 | 0/8 | 13/40 | 3/38 | 4/22 |
| Age, Continuous(Years) | Group A1: Phase Ib Mosunetuzumab + CHOP | Group A2: Phase Ib Mosunetuzumab + CHOP | Group B: Phase Ib Mosunetuzumab + CHP-Pola | Group C: Phase II Mosunetuzumab + CHOP | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 72.0 ± 13.0 | 71.3 ± 3.4 | 60.1 ± 18.0 | 63.4 ± 11.0 | 65.0 ± 10.0 | 57.7 ± 14.3 | 63.2 ± 12.1 |
| Sex: Female, Male(Participants) | Group A1: Phase Ib Mosunetuzumab + CHOP | Group A2: Phase Ib Mosunetuzumab + CHOP | Group B: Phase Ib Mosunetuzumab + CHP-Pola | Group C: Phase II Mosunetuzumab + CHOP | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 1 | 3 | 18 | 14 | 8 | 44 |
| Male | 3 | 3 | 5 | 22 | 26 | 14 | 73 |
| Ethnicity (NIH/OMB)(Participants) | Group A1: Phase Ib Mosunetuzumab + CHOP | Group A2: Phase Ib Mosunetuzumab + CHOP | Group B: Phase Ib Mosunetuzumab + CHP-Pola | Group C: Phase II Mosunetuzumab + CHOP | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 3 | 3 | 2 | 3 | 12 |
| Not Hispanic or Latino | 3 | 3 | 5 | 36 | 35 | 18 | 100 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 3 | 1 | 5 |
| Race (NIH/OMB)(Participants) | Group A1: Phase Ib Mosunetuzumab + CHOP | Group A2: Phase Ib Mosunetuzumab + CHOP | Group B: Phase Ib Mosunetuzumab + CHP-Pola | Group C: Phase II Mosunetuzumab + CHOP | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 | 10 | 5 | 0 | 15 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| White | 3 | 4 | 8 | 28 | 30 | 20 | 93 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 2 | 4 | 1 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Mar 2019 to primary completion in Oct 2023, 55 months.
Results were first posted in Dec 2024, 1 year 2 months after primary completion.
Of 94 phase 1/2 interventional studies under Lymphoma, B-Cell, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 55 and three quarters within 96. This study's 55 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Mosunetuzumab · Polatuzumab vedotin